Autolus Therapeutics AUTL 深 沪
等待开盘 06-26 09:30:00 美东时间
1.61
+0.005
+0.31%
华盛通- 最 高1.68
- 今 开1.61
- 成交量 57.84万股
- 最 低 1.48
- 昨 收 1.605
- 总市值 14.64万
- 52周最高 2.70
- 市盈率 静 --
- 换手率 636.15%
- 52周最低 1.175
- 委 比 4.97%
- 总股本 9.09万
- 历史最高 53.24
- 量 比 0.57
- 振 幅 12.46%
- 历史最低 1.10
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunic Appoints Michael W. Bonney As Board Chairman
Mr. Bonney brings more than three decades of leadership experience in the biopharmaceutical industry, including significant expertise in multiple sclerosis (MS) and broader central nervous system markets. Notably, during
05-19 18:32
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
Autolus Therapeutics reports updated long-term data from the FELIX study of obe-cel in adult r/r B-ALL patients, showing a median response duration of 42.6 months, with over half of patients in remission at 24 months and 38% not requiring subsequent therapy by month 33. The results suggest obe-cel may offer durable, definitive treatment for some patients.
2025-06-12 06:00
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics (Nasdaq: AUTL) announced its participation in three upcoming investor conferences: June 3 in Chicago, June 5 in New York, and June 11 in Miami.
2025-05-29 20:05
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Autolus Therapeutics' obe-cel CAR T-cell therapy received a positive CHMP opinion, based on the FELIX trial showing high response rates and low toxicity for adult r/r B-ALL patients. The EC is expected to decide on conditional marketing authorization within two months, following FDA and MHRA approvals.
2025-05-23 12:30
European Equities Traded in the US as American Depositary Receipts Edge Lower Friday; Set to End Week Up 0.5%
11:10 AM EDT, 08/30/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts edged lower late Friday morning, nudging down 0.03% to 1,476.31 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and ...
2024-08-30 23:10
Autolus Therapeutics to Present Tumor Burden-Guided Dosing Data at SOHO 2024
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces a poster presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting being held September 4-7, 2024 in Houston, Texas. These data demonst...
2024-08-27 19:02
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
11:19 AM EDT, 08/15/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were higher late Thursday morning, rising 1.22% to 1,444.66 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and in...
2024-08-15 23:19
